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Abstract
Aims/hypothesis In epidemiological and genetic studies
surrogate indices are needed to investigate insulin resis-
tance in different insulin-sensitive tissues. Our objective
was to develop a surrogate index for hepatic insulin
resistance.
Methods A sample of 368 non-diabetic participants (age
43.0±8.2 years, BMI 26.0±4.0 kg/m2; mean±SD) whose
endogenous glucose production (EGP) was measured with
[6-62H2]glucose in the fasting state and during the
euglycaemic–hyperinsulinaemic clamp were included in
the study. EGP multiplied by fasting plasma insulin (FPI)
concentration was the reference measurement for liver
insulin resistance (liver IR). Liver IR index was calculated
with linear regression analysis including age, obesity
indices, lipids, lipoproteins and several variables regulating
glucose metabolism.
Results The following variables were significantly associated
with liver IR in multiple forward stepwise regression
analysis: insulin AUC in an OGTT, fat mass, HDL-
cholesterol and BMI. Liver IR index correlated signifi-
cantly with EGP×FPI (r=0.65, p<0.001). In participants
with abnormal glucose tolerance, the correlation of liver
IR with EGP×FPI was slightly stronger (r=0.69, p<
0.001) than in those with normal glucose tolerance (r=0.62,
p<0.001).
Conclusions/interpretation We generated a novel surrogate
index for liver insulin resistance correlating strongly with
EGP×FPI.
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Abbreviations
EGP Endogenous glucose production
FPI Fasting plasma insulin
Liver IR Liver insulin resistance
RISC Relationship between insulin sensitivity and
cardiovascular disease
Introduction
Insulin resistance and beta cell failure represent the core
pathophysiological defects in type 2 diabetes [1]. Insulin
resistance, which is also observed in non-diabetic patients,
clusters with other metabolic and cardiovascular risk factors,
occurring in multiple insulin-sensitive tissues, including
skeletal muscle, liver and adipose tissue [1].
The liver plays an important role in the development of
hyperglycaemia and dyslipidaemia. Insulin resistance in
liver is manifested by overproduction of glucose in the basal
state despite the presence of fasting hyperinsulinaemia,
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indicating impaired suppression of hepatic glucose produc-
tion in response to insulin [2]. Hepatic insulin resistance
contributes to fasting and postprandial hyperglycaemia in
prediabetic and type 2 diabetic individuals [3, 4]. Thus,
elevated endogenous glucose production (EGP) in the
presence of high fasting plasma insulin (FPI) concentration
suggests hepatic insulin resistance. Since the majority of
EGP is known to occur in the liver, EGP×FPI is considered
to be the reference measure for hepatic insulin resistance
[5]. The assessment of hepatic insulin resistance by clamp
combined with tracer techniques is laborious and expen-
sive, and therefore not feasible for large epidemiological
and genetic studies.
Surrogate markers of insulin resistance are widely used
in population-based studies. Only one previous surrogate
index for hepatic insulin resistance has been published. The
study, by Abdul Ghani et al. [6], included 155 Mexican–
American participants (100 with normal glucose tolerance,
55 with impaired glucose tolerance) who were mostly obese
(mean BMI 30.4 kg/m2). Their surrogate index was
calculated as the product of insulin and glucose AUCs
during the first 30 min of an OGTT, and it had a correlation
of 0.64 with EGP×FPI.
We aimed to generate a new surrogate liver insulin
resistance (liver IR) index, which would include not only
variables from an OGTT, but also various metabolic traits/
markers observed in hepatic insulin resistance. To this end,
we validated our index in a large sample of healthy non-
diabetic white Europeans [7].
Methods
Study participants A sample of 368 clinically healthy non-
diabetic men (n=183) and women (n=185) from the
Relationship between Insulin Sensitivity and Cardiovascular
Disease (RISC) study (age 43.0±8.2 years, BMI 26.0±
4.0 kg/m2; mean±SD) with complete data was used to
develop and validate our surrogate index of liver IR. In this
sample, 288 participants had normal glucose tolerance and
80 had either impaired fasting glucose, impaired glucose
tolerance or both [8]. All participants were recruited from
19 research centres in 14 European countries. The protocol
was approved by the local Ethics Committees and all
participants gave written informed consent. The inclusion
of study participants and the study protocol have been
described previously [7].
EGP EGP was measured with [6-62H2]glucose in the
fasting state and during the euglycaemic–hyperinsulinaemic
clamp. A primed continuous infusion of labelled glucose
was continued for 2 h and blood samples obtained during
the last 20 min of the equilibration period to measure the
plasma tracer concentration. EGP during the clamp was
measured assuming a monocompartment model for glucose
kinetics. Insulin sensitivity was measured by the euglycaemic
insulin clamp technique [5], using a primed infusion rate of
1 mUmin−1kg−1, followed by an exogenous glucose
infusion.
OGTT A 2 h OGTT (75 g glucose) was performed after an
overnight fast and samples for plasma glucose, insulin and
NEFA were drawn.
Laboratory measurements Plasma glucose was measured
by the glucose oxidase method. Plasma insulin concen-
trations were measured by radioimmunoassay. Body com-
position was determined by bioelectrical impedance
(TBF-300 Bioimpedance Balance; Tanita International
Division, Middlesex, UK). Total plasma adiponectin
was measured using a validated in-house time-resolved
immunofluorimetric assay. Glucagon was measured by a
glucagon assay (developed in J. Holst’s laboratory,
University of Copenhagen, Denmark) and NEFA by
spectrophotometry. Plasma HDL-cholesterol, triacylgly-
cerol and alanine aminotransferase were measured by
standard methods.
Calculations The trapezoidal method was used to calculate
glucose and insulin AUC in an OGTT based on 0, 30 and
120 min data (AUC 0–120 min). The hepatic insulin
resistance index proposed by Abdul-Ghani et al. [6] was
calculated as described.
Statistical analysis Pearson correlation analysis was per-
formed between EGP×FPI and all clinical and laboratory
variables such as glucose and insulin AUC from an
OGTT, fasting NEFA, lipoproteins, measures of adiposity,
alanine transaminase, adiponectin and glucagon. Forward
multiple stepwise regression analysis was applied to
identify the statistically significant determinants of EGP×
FPI. All variables were log-transformed due to their
skewed distribution, except for liver IR index, which
was normally distributed. The effect of sex and obesity on
liver IR index was tested using a univariate linear
regression model.
Results
Liver IR index Variables with a correlation (r) of r>0.2
with EGP×FPI, including BMI, waist, fat mass (%), HDL-
cholesterol, total triacylglycerol, adiponectin, glucose AUC
0–120 min and insulin AUC 0–120 min, were included in
multiple stepwise linear regression analysis (Table 1). Four
Diabetologia (2011) 54:540–543 541
of these variables remained statistically significant in the
regression model, giving the following formula for liver IR
index:
Liver IR index ¼
0:091þ ðlog insulin AUC 0120min 0:400Þ
þ ðlog fatmass% 0:346Þ  logHDL<cholesterol  0:408ð Þ
þ log BMI 0:435ð Þ
Liver IR index correlated significantly with EGP×FPI
(r=0.65, p<0.001; Fig. 1) and exhibited a slightly stronger
correlation with EGP×FPI in glucose-intolerant (r=0.69)
than in normoglycaemic participants (r=0.62). Liver IR
index performed somewhat better in obese participants
(BMI >25 kg/m2, n=206, r=0.62, p<0.001) than in lean
participants (BMI ≤25 kg/m2, n=162, r=0.53, p<0.001).
The RISC study included men and women. We therefore
tested whether sex had any influence on the liver IR index.
The correlation coefficients of the liver IR index with
EGP×FPI were similar in both sexes (r=0.65).
We repeated our calculations by replacing glucose and
insulin AUC 0–120 min by their ratio (insulin AUC 0–
120min: glucose AUC 0–120min).With this ratio, the model
identified the same variables in the regression equation as did
the liver IR index, but the correlation with EGP×FPI was not
better (r=0.64). When we added EGP measurement during
the clamp to basal EGP (i.e. fasting EGP+clamp EGP), the
liver IR index correlated significantly but less strongly (r=
0.59, p<0.001) with ðfasting EGPþ clamp EGPÞ  FPI.
The hepatic insulin resistance index proposed by Abdul-
Ghani et al. [6] had a lower correlation of r=0.58 (p<
0.001) with EGP×FPI in our study. The correlation was
somewhat weaker in participants with normoglycaemia (r=
0.56, p<0.001) than in those with abnormal glucose
tolerance (r=0.59, p<0.001).
Discussion
We developed a novel surrogate marker of hepatic insulin
resistance. It takes into consideration not only OGTT-
derived measures of glucose and insulin, but also various
metabolic traits related to hepatic insulin resistance, e.g.
BMI, fat mass and HDL-cholesterol. Obesity is a known
risk factor for hepatic insulin resistance; moreover, intra-
abdominal visceral fat and abdominal subcutaneous fat also
correlate positively with hepatic insulin resistance [9].
Hepatic insulin resistance also reduces HDL-cholesterol
level [10].
Hepatic insulin sensitivity determines EGP, which is the
main regulator of glucose level in the fasting state. In
individuals with abnormal glucose tolerance, and especially
in individuals with type 2 diabetes, suppression of EGP is
inadequate and contributes to fasting and postprandial
hyperglycaemia [3, 4]. Since insulin inhibits EGP, incre-
ments in insulin concentrations during an OGTT or clamp
exert an inhibitory effect on EGP. We further examined our
liver IR index by adding EGP measurement during the
clamp to basal EGP, but this did not alter the correlation
much, indicating that our index seems to be a good marker
for liver IR not only in the fasting, but also in the insulin-
stimulated state.
In the study by Abdul-Ghani et al. [6], the correlation
of the hepatic insulin resistance index, calculated as a
product of glucose and insulin AUCs during 0–30 min,
Fig. 1 Pearson correlation of liver IR index as a function of EGP
multiplied by FPI (r=0.65, p<0.001). Circles indicate the participants
and the diagonal indicates linear regression line
Table 1 Pearson correlations of clinical and laboratory measurements
with hepatic insulin resistance, defined by the product of EGP and FPI
Variable r
Age 0.027
Waist 0.311***
Fat mass 0.410***
BMI 0.454***
NEFA 0.078
HDL-cholesterol −0.299***
Triacylglycerol 0.306***
Alanine transaminase 0.193***
Adiponectin −0.218***
Glucagon 0.080
Glucose AUC 0–120 min 0.236***
Insulin AUC 0–120 min 0.562***
*p<0.001
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with EGP×FPI, was 0.64 (n=155). In the RISC study,
however, which included more than twice as many
participants than that cited, the correlation was somewhat
weaker (r=0.58, p<0.001). The differences between these
results may be due to the smaller sample size in the study
by Abdul-Ghani et al. [6] and the larger number of obese
participants in their study. Our liver IR index correlated
more strongly with EGP×FPI in obese participants (r=
0.62) than in lean participants (r=0.53), which was also
reported for the index proposed by Abdul-Ghani et al. [6],
where the difference was larger (r=0.65 and r=0.31
respectively). Therefore, our liver IR index is more
suitable for studies including normal-weight and obese
participants.
The strength of our study is the availability of gold
standard measurements to estimate hepatic insulin resis-
tance (tracers, clamp) in a large European cohort. Further-
more, our liver IR index takes into account clinical and
metabolic traits that are characteristic features of hepatic
insulin resistance. Nevertheless, our liver IR index will
need to be validated in other studies.
In conclusion, we developed a novel surrogate index for
hepatic insulin resistance and provided evidence that this
index performs well in non-diabetic individuals indepen-
dently of glucose tolerance and obesity.
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